REIT - Healthcare Facilities
Compare Stocks
5 / 10Stock Comparison
AHR vs WELL vs VTR vs HR vs DOC
Revenue, margins, valuation, and 5-year total return — side by side.
REIT - Healthcare Facilities
REIT - Healthcare Facilities
REIT - Healthcare Facilities
REIT - Healthcare Facilities
AHR vs WELL vs VTR vs HR vs DOC — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | REIT - Healthcare Facilities | REIT - Healthcare Facilities | REIT - Healthcare Facilities | REIT - Healthcare Facilities | REIT - Healthcare Facilities |
| Market Cap | $9.52B | $149.25B | $41.15B | $6.98B | $13.67B |
| Revenue (TTM) | $2.26B | $11.63B | $6.13B | $1.15B | $2.87B |
| Net Income (TTM) | $70M | $1.43B | $260M | $-201M | $222M |
| Gross Margin | 15.2% | 39.1% | -4.3% | -9.7% | 21.2% |
| Operating Margin | 7.5% | 4.4% | 13.4% | 19.5% | 18.3% |
| Forward P/E | 66.0x | 78.4x | 118.0x | — | 100.9x |
| Total Debt | $1.59B | $21.38B | $13.22B | $4.15B | $10.44B |
| Cash & Equiv. | $115M | $5.03B | $741M | $26M | $538M |
AHR vs WELL vs VTR vs HR vs DOC — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Feb 24 | May 26 | Return |
|---|---|---|---|
| American Healthcare… (AHR) | 100 | 362.8 | +262.8% |
| Welltower Inc. (WELL) | 100 | 231.1 | +131.1% |
| Ventas, Inc. (VTR) | 100 | 204.6 | +104.6% |
| Healthcare Realty T… (HR) | 100 | 145.1 | +45.1% |
| Healthpeak Properti… (DOC) | 100 | 117.4 | +17.4% |
Price return only. Dividends and distributions are not included.
Quick Verdict: AHR vs WELL vs VTR vs HR vs DOC
Each card shows where this stock fits in a portfolio — not just who wins on paper.
AHR is the #2 pick in this set and the best alternative if long-term compounding is your priority.
- 292.2% 10Y total return vs WELL's 223.1%
- Better valuation composite
- +54.9% vs DOC's +21.0%
WELL carries the broadest edge in this set and is the clearest fit for growth exposure and sleep-well-at-night.
- Rev growth 35.8%, EPS growth -11.5%, 3Y rev CAGR 22.7%
- Lower volatility, beta 0.13, Low D/E 49.5%, current ratio 5.34x
- 35.8% FFO/revenue growth vs HR's -6.9%
- 12.3% margin vs HR's -17.5%
VTR ranks third and is worth considering specifically for income & stability.
- Dividend streak 1 yrs, beta 0.01, yield 2.1%
- Beta 0.01 vs DOC's 0.52, lower leverage
HR is the clearest fit if your priority is defensive.
- Beta 0.13, yield 5.5%, current ratio 1.75x
DOC is the clearest fit if your priority is dividends.
- 6.2% yield, 1-year raise streak, vs WELL's 1.3%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 35.8% FFO/revenue growth vs HR's -6.9% | |
| Value | Better valuation composite | |
| Quality / Margins | 12.3% margin vs HR's -17.5% | |
| Stability / Safety | Beta 0.01 vs DOC's 0.52, lower leverage | |
| Dividends | 6.2% yield, 1-year raise streak, vs WELL's 1.3% | |
| Momentum (1Y) | +54.9% vs DOC's +21.0% | |
| Efficiency (ROA) | 2.3% ROA vs HR's -2.1%, ROIC 0.5% vs 0.7% |
AHR vs WELL vs VTR vs HR vs DOC — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
AHR vs WELL vs VTR vs HR vs DOC — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
AHR leads in 2 of 6 categories
WELL leads 1 • VTR leads 0 • HR leads 0 • DOC leads 0 • 3 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
WELL leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
WELL is the larger business by revenue, generating $11.6B annually — 10.1x HR's $1.1B. WELL is the more profitable business, keeping 12.3% of every revenue dollar as net income compared to HR's -17.5%. On growth, WELL holds the edge at +40.3% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $2.3B | $11.6B | $6.1B | $1.1B | $2.9B |
| EBITDAEarnings before interest/tax | $376M | $2.8B | $2.3B | $767M | $1.6B |
| Net IncomeAfter-tax profit | $70M | $1.4B | $260M | -$201M | $222M |
| Free Cash FlowCash after capex | $225M | $2.5B | $1.4B | $201M | $1.2B |
| Gross MarginGross profit ÷ Revenue | +15.2% | +39.1% | -4.3% | -9.7% | +21.2% |
| Operating MarginEBIT ÷ Revenue | +7.5% | +4.4% | +13.4% | +19.5% | +18.3% |
| Net MarginNet income ÷ Revenue | +3.1% | +12.3% | +4.2% | -17.5% | +7.7% |
| FCF MarginFCF ÷ Revenue | +10.0% | +21.9% | +22.4% | +17.5% | +40.2% |
| Rev. Growth (YoY)Latest quarter vs prior year | +11.3% | +40.3% | +22.0% | -10.5% | +7.1% |
| EPS Growth (YoY)Latest quarter vs prior year | +128.8% | +22.5% | 0.0% | +99.8% | +3.6% |
Valuation Metrics
Evenly matched — AHR and HR and DOC each lead in 2 of 6 comparable metrics.
Valuation Metrics
At 118.1x trailing earnings, AHR trades at a 40% valuation discount to DOC's 196.6x P/E. On an enterprise value basis, DOC's 14.7x EV/EBITDA is more attractive than WELL's 66.4x.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $9.5B | $149.2B | $41.1B | $7.0B | $13.7B |
| Enterprise ValueMkt cap + debt − cash | $11.0B | $165.6B | $53.6B | $11.1B | $23.6B |
| Trailing P/EPrice ÷ TTM EPS | 118.10x | 153.25x | 160.26x | -28.16x | 196.60x |
| Forward P/EPrice ÷ next-FY EPS est. | 65.97x | 78.42x | 118.01x | — | 100.92x |
| PEG RatioP/E ÷ EPS growth rate | 1.77x | — | — | — | — |
| EV / EBITDAEnterprise value multiple | 30.93x | 66.40x | 24.31x | 16.84x | 14.70x |
| Price / SalesMarket cap ÷ Revenue | 4.21x | 13.99x | 7.05x | 5.91x | 4.84x |
| Price / BookPrice ÷ Book value/share | 2.46x | 3.35x | 3.18x | 1.50x | 1.65x |
| Price / FCFMarket cap ÷ FCF | 57.37x | 52.41x | 31.25x | 54.95x | 11.92x |
Profitability & Efficiency
AHR leads this category, winning 5 of 9 comparable metrics.
Profitability & Efficiency
WELL delivers a 3.5% return on equity — every $100 of shareholder capital generates $3 in annual profit, vs $-4 for HR. AHR carries lower financial leverage with a 0.47x debt-to-equity ratio, signaling a more conservative balance sheet compared to DOC's 1.26x. On the Piotroski fundamental quality scale (0–9), WELL scores 7/9 vs DOC's 4/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | +2.6% | +3.5% | +2.1% | -4.3% | +2.6% |
| ROA (TTM)Return on assets | +1.5% | +2.3% | +1.0% | -2.1% | +1.1% |
| ROICReturn on invested capital | +2.8% | +0.5% | +2.5% | +0.7% | +2.3% |
| ROCEReturn on capital employed | +3.4% | +0.6% | +3.2% | +1.0% | +2.8% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 7 | 6 | 7 | 4 |
| Debt / EquityFinancial leverage | 0.47x | 0.49x | 1.05x | 0.89x | 1.26x |
| Net DebtTotal debt minus cash | $1.5B | $16.3B | $12.5B | $4.1B | $9.9B |
| Cash & Equiv.Liquid assets | $115M | $5.0B | $741M | $26M | $538M |
| Total DebtShort + long-term debt | $1.6B | $21.4B | $13.2B | $4.1B | $10.4B |
| Interest CoverageEBIT ÷ Interest expense | 1.57x | 0.26x | 1.40x | -0.21x | 1.78x |
Total Returns (Dividends Reinvested)
AHR leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in AHR five years ago would be worth $39,221 today (with dividends reinvested), compared to $8,448 for DOC. Over the past 12 months, AHR leads with a +54.9% total return vs DOC's +21.0%. The 3-year compound annual growth rate (CAGR) favors AHR at 57.7% vs DOC's 3.9% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | +5.5% | +14.3% | +12.6% | +19.4% | +23.9% |
| 1-Year ReturnPast 12 months | +54.9% | +42.7% | +33.9% | +38.2% | +21.0% |
| 3-Year ReturnCumulative with dividends | +292.2% | +189.5% | +94.2% | +17.5% | +12.1% |
| 5-Year ReturnCumulative with dividends | +292.2% | +202.3% | +74.8% | +1.1% | -15.5% |
| 10-Year ReturnCumulative with dividends | +292.2% | +223.1% | +65.0% | +39.6% | +11.2% |
| CAGR (3Y)Annualised 3-year return | +57.7% | +42.5% | +24.8% | +5.5% | +3.9% |
Risk & Volatility
Evenly matched — VTR and DOC each lead in 1 of 2 comparable metrics.
Risk & Volatility
VTR is the less volatile stock with a 0.01 beta — it tends to amplify market swings less than DOC's 0.52 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. DOC currently trades 99.9% from its 52-week high vs AHR's 90.7% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.23x | 0.13x | 0.01x | 0.13x | 0.52x |
| 52-Week HighHighest price in past year | $54.67 | $219.59 | $88.50 | $20.46 | $19.68 |
| 52-Week LowLowest price in past year | $32.15 | $142.65 | $61.76 | $14.09 | $15.70 |
| % of 52W HighCurrent price vs 52-week peak | +90.7% | +97.0% | +97.8% | +97.7% | +99.9% |
| RSI (14)Momentum oscillator 0–100 | 51.8 | 60.2 | 56.2 | 77.5 | 76.9 |
| Avg Volume (50D)Average daily shares traded | 2.3M | 2.6M | 3.4M | 3.5M | 8.2M |
Analyst Outlook
Evenly matched — WELL and DOC each lead in 1 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: AHR as "Buy", WELL as "Buy", VTR as "Buy", HR as "Hold", DOC as "Buy". Consensus price targets imply 14.4% upside for AHR (target: $57) vs -9.2% for DOC (target: $18). For income investors, DOC offers the higher dividend yield at 6.20% vs WELL's 1.30%.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Buy | Hold | Buy |
| Price TargetConsensus 12-month target | $56.75 | $226.50 | $90.80 | $19.33 | $17.86 |
| # AnalystsCovering analysts | 11 | 34 | 32 | 29 | 40 |
| Dividend YieldAnnual dividend ÷ price | +2.0% | +1.3% | +2.1% | +5.5% | +6.2% |
| Dividend StreakConsecutive years of raises | 1 | 2 | 1 | 0 | 1 |
| Dividend / ShareAnnual DPS | $0.98 | $2.76 | $1.86 | $1.11 | $1.22 |
| Buyback YieldShare repurchases ÷ mkt cap | +0.0% | 0.0% | 0.0% | +0.1% | +0.7% |
AHR leads in 2 of 6 categories (Profitability & Efficiency, Total Returns). WELL leads in 1 (Income & Cash Flow). 3 tied.
AHR vs WELL vs VTR vs HR vs DOC: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is AHR or WELL or VTR or HR or DOC a better buy right now?
For growth investors, Welltower Inc.
(WELL) is the stronger pick with 35. 8% revenue growth year-over-year, versus -6. 9% for Healthcare Realty Trust Incorporated (HR). American Healthcare REIT, Inc. (AHR) offers the better valuation at 118. 1x trailing P/E (66. 0x forward), making it the more compelling value choice. Analysts rate American Healthcare REIT, Inc. (AHR) a "Buy" — based on 11 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — AHR or WELL or VTR or HR or DOC?
On trailing P/E, American Healthcare REIT, Inc.
(AHR) is the cheapest at 118. 1x versus Healthpeak Properties, Inc. at 196. 6x. On forward P/E, American Healthcare REIT, Inc. is actually cheaper at 66. 0x.
03Which is the better long-term investment — AHR or WELL or VTR or HR or DOC?
Over the past 5 years, American Healthcare REIT, Inc.
(AHR) delivered a total return of +292. 2%, compared to -15. 5% for Healthpeak Properties, Inc. (DOC). Over 10 years, the gap is even starker: AHR returned +292. 2% versus DOC's +11. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — AHR or WELL or VTR or HR or DOC?
By beta (market sensitivity over 5 years), Ventas, Inc.
(VTR) is the lower-risk stock at 0. 01β versus Healthpeak Properties, Inc. 's 0. 52β — meaning DOC is approximately 5359% more volatile than VTR relative to the S&P 500. On balance sheet safety, American Healthcare REIT, Inc. (AHR) carries a lower debt/equity ratio of 47% versus 126% for Healthpeak Properties, Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — AHR or WELL or VTR or HR or DOC?
By revenue growth (latest reported year), Welltower Inc.
(WELL) is pulling ahead at 35. 8% versus -6. 9% for Healthcare Realty Trust Incorporated (HR). On earnings-per-share growth, the picture is similar: American Healthcare REIT, Inc. grew EPS 244. 8% year-over-year, compared to -72. 2% for Healthpeak Properties, Inc.. Over a 3-year CAGR, WELL leads at 22. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — AHR or WELL or VTR or HR or DOC?
Welltower Inc.
(WELL) is the more profitable company, earning 8. 8% net margin versus -20. 8% for Healthcare Realty Trust Incorporated — meaning it keeps 8. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: DOC leads at 19. 3% versus 3. 3% for WELL. At the gross margin level — before operating expenses — WELL leads at 39. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is AHR or WELL or VTR or HR or DOC more undervalued right now?
On forward earnings alone, American Healthcare REIT, Inc.
(AHR) trades at 66. 0x forward P/E versus 118. 0x for Ventas, Inc. — 52. 0x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for AHR: 14. 4% to $56. 75.
08Which pays a better dividend — AHR or WELL or VTR or HR or DOC?
All stocks in this comparison pay dividends.
Healthpeak Properties, Inc. (DOC) offers the highest yield at 6. 2%, versus 1. 3% for Welltower Inc. (WELL).
09Is AHR or WELL or VTR or HR or DOC better for a retirement portfolio?
For long-horizon retirement investors, Ventas, Inc.
(VTR) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 01), 2. 1% yield). Both have compounded well over 10 years (VTR: +65. 0%, DOC: +11. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between AHR and WELL and VTR and HR and DOC?
Both stocks operate in the Real Estate sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: AHR is a small-cap quality compounder stock; WELL is a mid-cap high-growth stock; VTR is a mid-cap high-growth stock; HR is a small-cap income-oriented stock; DOC is a mid-cap income-oriented stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.